AKTive-001: a Phase 1/1b Multiple Cohort Trial of ALTA2618 in Patients with Advanced Solid Tumors with AKT1 E17K Mutation

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 16 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ALTA 2618 (Primary)
Indications Breast cancer; Endometrial cancer; Gynaecological cancer; HER2 negative breast cancer; Male breast cancer; Solid tumours
Focus Adverse reactions; First in man
Acronyms AKTive-001
Sponsors Alterome Therapeutics

13 Dec 2024 Study design were presented at the 47th Annual San Antonio Breast Cancer Symposium
11 Dec 2024 According to the Florida Cancer Specialists & Research Institute Media Release, data from this study studies being presented this week at the San Antonio Breast Cancer Symposium.
30 Oct 2024 According to an Alterome Therapeutics media release, company announced announced the dosing of the first patient in AKTive-001 and additional clinical sites across Europe, Asia and Australia will initiate enrollment over the next year.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com